Shire announced that the FDA has approved Adynovate (recombinant factor VIII) for hemophilia A, in pediatric patients under 12 years...
Baxalta has announced initial results from a Phase III clinical trial of Adynovate (recombinant factor VIII), an extended circulating half-life...
Takeda announced results from its phase IIIb/IV PROPEL trial for Adynovate (recombinant factor VIII), a PROspective, randomized, multi-center study comparing...
Baxalta announced the publication of the complete data from the Phase II/III pivotal study and Phase I trial of BAX...
Baxalta has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval of Adynovi, an extended...